Burkhardt Soares S, Kukuk S, Brandt A S, Fehr A, Roth S
Klinik für Urologie und Kinderurologie, HELIOS Klinikum Wuppertal, Universitätsklinikum der Universität Witten/Herdecke, Heusnerstrasse 40, 42283 Wuppertal, Deutschland.
Urologe A. 2008 Apr;47(4):489-499. doi: 10.1007/s00120-008-1705-6.
Retroperitoneal Fibrosis (RPF) is a rare disease with peak incidence in the fifth to seventh decades of life. Its etiology remains to a great extent unclear; however, many characteristics of the disease suggest an autoimmune origin. Distinction is made between primary/idiopathic and secondary RPF. Symptoms may be general/nonspecific or localized (due to replacement or compression of organs). In addition to patient history, laboratory analysis and radiologic examinations, diagnosis often requires biopsy taken from the area affected. After restoring the function of involved (hollow) organs, medical therapy with prednisone, immunosuppressive drugs or tamoxifen is aimed at converting active disease to stable disease. However, some patients require ureteral surgery due to unsuccessful treatment. Life-long follow-up of patients is necessary since RPF can show a chronically relapsing course.
腹膜后纤维化(RPF)是一种罕见疾病,发病高峰在50至70岁之间。其病因在很大程度上仍不清楚;然而,该疾病的许多特征提示其起源于自身免疫。RPF可分为原发性/特发性和继发性。症状可能是全身性/非特异性的,也可能是局部性的(由于器官被替代或受压)。除患者病史、实验室分析和影像学检查外,诊断通常需要从受累区域进行活检。在恢复受累(中空)器官的功能后,使用泼尼松、免疫抑制药物或他莫昔芬进行药物治疗旨在将活动性疾病转变为稳定疾病。然而,一些患者因治疗失败而需要进行输尿管手术。由于RPF可呈慢性复发病程,因此对患者进行终身随访是必要的。